Company Description
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally.
It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers.
In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers.
Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals.
Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors.
The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003.
Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
| Country | United States |
| Founded | 1946 |
| IPO Date | Apr 11, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,940 |
| CEO | Jack Bendheim |
Contact Details
Address: Glenpointe Centre East, 3rd Floor Teaneck, New Jersey 07666-6712 United States | |
| Phone | 201 329 7300 |
| Website | pahc.com |
Stock Details
| Ticker Symbol | PAHC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001069899 |
| CUSIP Number | 71742Q106 |
| ISIN Number | US71742Q1067 |
| Employer ID | 13-1840497 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jack Clifford Bendheim | Chairman, President and Chief Executive Officer |
| Glenn C. David | Chief Financial Officer |
| Larry L. Miller | Chief Operating Officer |
| Daniel M. Bendheim J.D. | Executive Vice President of Corporate Strategy and Director |
| Rob Aukerman | President of North America Region |
| Judith A. Weinstein | Senior Vice President, General Counsel and Corporate Secretary |
| Lisa A. Escudero | Senior Vice President of Human Resources |
| Jonathan Bendheim | President of MACIE Region, GM of Israel Operations and Director |
| Ramon Fuenmayor | President South America Region |
| Samson Li | President of Asia Pacific Region |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 16, 2024 | SCHEDULE 13G | Filing |